Warning: members of the public are being contacted by people claiming to work for AXA Investment Managers UK Limited.  Find out more information and what to do by clicking here.

UK Mid Cap strategy - February 2022

  • 15 March 2022 (5 min read)

The UK stock market is home to numerous growing well managed businesses that generate cash

  • The UK equity market provided quite divergent returns in February
  • UK inflation hits 30-year high with CPI at 5.5% driven by Russia-Ukraine war
  • We exited our holdings in Bridgepoint and Synairgen

What’s happening?

Equity markets started February on the back foot after a tough start to the year. Inflation, interest rate concerns and volatility picked up further as Russia launched a full-scale invasion of Ukraine. Oil prices spiked to a seven-year high, soaring to $105 a barrel and gold prices jumped as investors rushed to safe-haven assets, with the precious metal hitting $1,970 per ounce.

There was however positive UK GDP data over the month as Britain’s economy continued its recovery from the Covid-19 pandemic, recording a smaller hit from the spread of the Omicron variant than feared. The data capped a turbulent two years that saw the collapse and then a rebound of the economy, growing 7.5% in 2021, the biggest annual rise since 1941.

The recent increase in interest rates has been justified by the inflation numbers in the UK, which reached a 30-year high in January as the Consumer Price Index hit 5.5%. The Bank of England (BoE) has forecasted inflation will get as high as 7.5% in April. However, this does not factor in the recent spike in oil on the back of the Ukraine conflict. The BoE increased interest rates from 0.25% to 0.5% at the beginning of February and is expected to raise rates again in March.

The UK equity market provided quite divergent returns in February with the resource heavy FTSE 100 again holding up well in the face of a broader market sell-off. The FTSE All Share fell -0.46%1 , the FTSE 100 rose +0.32% and the FTSE 250 (ex-Investment Companies) fell -3.98%, while the FTSE Small Cap (ex-Investment companies) fell -3.86%.

Portfolio positioning and performance

Over the month, the strategy underperformed the FTSE 250 ex Investment Trusts. The Energy and Technology sectors contributed positively to relative performance, whereas our Industrials and Healthcare contributed negatively.

Positions which contributed positively over the month included Chemring (defence), Energean (oil & gas), Serica (oil & gas) and not owning Marks and Spencer Group (fashion and food retailer). Both Energean and Serica benefitted from the significant increase in oil and gas prices. Synairgen (drug development) and Future (specialty media) both detracted from performance, as did not owning Endeavour Mining. Synairgen’s price declined after the Phase 3 trial of its inhaled treatment for Covid-19 failed to meet its primary or key secondary efficacy endpoints. The rotation out of ‘growth’ investments into ‘value’ has been detrimental to performance and this goes some way to explaining the fall in the share price of Future.  The fundamentals of the business remain intact and we continue to support of the investment case.

Our strategy and investment philosophy remained unchanged in February. We continue to focus on well-capitalised companies that have growing profits, cash flows and, where appropriate, dividends. Market volatility was used to add to and reduce core holdings. Over the month, the holdings in Bridgepoint and Synairgen were sold.


Market direction continues to be shaped by inflation, interest rates and commodity prices. Inflation seems likely to increase further in the first half of the year from already high levels, particularly given the recent move in the oil price. The Russia-Ukraine conflict has however created incremental debate around the path of interest rates and Quantitative Tightening by Central Banks. Striking the right balance between controlling inflation and stimulating the economy will be a tricky balancing act, especially while governments withdraw their fiscal support.

At times of heightened risk and uncertainty, it is easy to focus exclusively on the macro and geopolitical newsflow and lose focus on the fundamental drivers of profitability and cashflow at the corporate level. The UK stock market is home to numerous growing businesses that generate cash, are well managed, have strong balance sheets and are operating in end markets that should expand over the long term. Earnings forecasts are set modestly and valuations are in many instances trading at multi year lows.

Our approach remains centred on owning good quality businesses that can reinvest and compound their returns over time. We continue to believe that understanding longer term structural trends and identifying responsible, reliable and ultimately sustainable companies, in a targeted, focused and active approach, remains the key to longer-term success.

No assurance can be given that the UK Mid Cap Strategy will be successful. Investors can lose some or all of their capital invested. The UK Mid Cap strategy is subject to risks including; Equity; Smaller companies risk; Liquidity risk.


Read the full article
Download article (223.89 KB)


    Not for Retail distribution: This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

    Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment.  Due to this and the initial charge that is usually made, an investment is not usually suitable as a short term holding.

    This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. The strategies discussed in this document may not be available in your jurisdiction.

    Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

    Please note that the management company reserves the right, at any time, to no longer market the product(s) mentioned in this communication in an European Union country by notification to its authority of supervision in accordance with European passport rules. In the event of dissatisfaction with the products or services, you have the right to make a complaint either with the marketer or directly with the management company (more information on our complaints policy available in English here). You also have the right to take legal or extra-judicial action at any time if you reside in one of the countries of the European Union. The European online dispute resolution platform allows you to enter a complaint form (by clicking here) and informs you, depending on your jurisdiction, about your means of redress (by clicking here).

    Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales No: 01431068. Registered Office 22 Bishopsgate, London EC2N 4AJ. In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.

    Risk Warning

    The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. 

    Are you an IFA or other Professional Investor ?

    Are you a financial advisor, institutional, or other professional investor?

    This section is for professional investors only. You need to confirm that you have the required investment knowledge and experience to view this content. This includes understanding the risks associated with investment products, and any other required qualifications according to the rules of your jurisdiction.